IBEX Technologies Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBT.V research report →
Companywww.ibex.ca
IBEX Technologies Inc. , through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid.
- CEO
- Paul Baehr
- IPO
- 1996
- Employees
- 9
- HQ
- Montreal, QC, CA
Price Chart
Valuation
- Market Cap
- $35.54M
- P/E
- 9.23
- P/S
- 4.74
- P/B
- 2.64
- EV/EBITDA
- 18.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 69.41%
- Op Margin
- -19.76%
- Net Margin
- 51.97%
- ROE
- 33.34%
- ROIC
- -9.71%
Growth & Income
- Revenue
- $7.49M · -5.08%
- Net Income
- $3.89M · 132.54%
- EPS
- $0.16 · 137.39%
- Op Income
- $-1,480,579
- FCF YoY
- -63.91%
Performance & Tape
- 52W High
- $1.45
- 52W Low
- $0.75
- 50D MA
- $1.34
- 200D MA
- $1.13
- Beta
- -0.04
- Avg Volume
- 63.92K
Get TickerSpark's AI analysis on IBT.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IBT.V Coverage
We haven't published any research on IBT.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IBT.V Report →